Advertisement

Management of Lung Diseases Associated with NTM Infection

  • Anne E. O’Donnell
Chapter
Part of the Respiratory Medicine book series (RM)

Abstract

A variety of lung diseases are either the cause or the consequence of nontuberculous mycobacterial (NTM) infections. The most common of these diseases are COPD, bronchiectasis, and fibrotic lung disease. Identifying and treating underlying lung diseases and coexisting infections with bacteria, fungi, and other organisms are critical elements for mitigating the impact of the NTM infection. The quality of life of patients with NTM infection can be improved by addressing coexisting lung disease and other complicating factors that contribute to morbidity and possibly mortality. A multimodality therapeutic approach and a collaborative approach between treating clinicians can maximize therapeutic benefit to the individual patient.

Keywords

Nontuberculous mycobacteria Bronchiectasis Chronic obstructive pulmonary disease 

References

  1. 1.
    Rosenzweig DY. Pulmonary mycobacterial infections due to mycobacterium intracellulare-avium complex. Chest. 1979;75:115–9.CrossRefGoogle Scholar
  2. 2.
    Wolinsky E. Nontuberculous mycobacterium and associated diseases. Am Rev Respir Dis. 1979;119:107–59.PubMedGoogle Scholar
  3. 3.
    Andrejak C, Nielsen R, Thomsen VO, Duhaut P, et al. Chronic respiratory disease, inhaled corticosteroids and risk of non-tuberculous mycobacteriosis. Thorax. 2013;68:256–62.CrossRefGoogle Scholar
  4. 4.
    Adjemian J, Olivier KN, Seitz AE, Holland SM, Prevots DR. Prevalence of nontuberculous mycobacterial lung disease in U.S. Medicare beneficiaries. Am J Respir Crit Care Med. 2012;185:881–6.CrossRefGoogle Scholar
  5. 5.
    Henkle E, Hedberg K, Schafer S, Novosad S, Winthrop KL. Population-based incidence of pulmonary nontuberculous mycobacterial disease in Oregon 2007 to 2012. Ann Am Thorac Soc. 2015;12:642–7.CrossRefGoogle Scholar
  6. 6.
    Olivier KN, Weber DJ, Wallace RJ, Faiz AR, et al. Nontuberculous mycobacteria in Cystic Fibrosis Study Group. Nontuberculous mycobacteria. I: multicenter prevalence study in cystic fibrosis. Am J Respir Crit Care Med. 2003;167:828–34.CrossRefGoogle Scholar
  7. 7.
    McShane PJ, Glassroth J. Pulmonary disease due to nontuberculous mycobacterium. Current state and new insights. Chest. 2015;148:1517–27.CrossRefGoogle Scholar
  8. 8.
    Ito Y, Hirai T, Fujita K, Maekawa K, et al. Increasing patients with pulmonary mycobacterium avium complex disease and associated underlying disease in Japan. J Infect Chemother. 2015;21:352–6.CrossRefGoogle Scholar
  9. 9.
    Brode SK, Jamieson FB, Ng R, et al. Risk of mycobacterial infections associated with rheumatoid arthritis in Ontario Canada. Chest. 2014;146:563–72.CrossRefGoogle Scholar
  10. 10.
    Lim J, Lyu J, Choi C-M, Oh Y-M, et al. Non-tuberculous mycobacterial diseases presenting as solitary pulmonary nodules. Int J Tuberc Lung Dis. 2010;14:1635–40.PubMedGoogle Scholar
  11. 11.
    Khoor A, Leslie KO, Tazelaar HD, Helmers RA, Colby TV. Diffuse pulmonary disease caused by nontuberculous mycobacteria in immunocompetent people (hot tub lung). Am J Clin Pathol. 2001;115:755–62.CrossRefGoogle Scholar
  12. 12.
    Char A, Hopkinson NS, Hansell DM, Nicholson AG, et al. Evidence of mycobacterial disease in COPD patients with lung volume reduction surgery; the importance of histologic assessment of specimens: a cohort study. BMC Pulm Med. 2014;12:124.CrossRefGoogle Scholar
  13. 13.
    Aitken MB, Limaye A, Pottinger P, et al. Respiratory outbreak of Mycobacterium abscessus subspecies massiliense in a lung transplant and cystic fibrosis center. Am J Respir Crit Care Med. 2012;185:231–2.CrossRefGoogle Scholar
  14. 14.
    Bryant JM, Grogono DM, Greaves D, Foweraker J, et al. Whole-genome sequencing to identify transmission of Mycobacterium abscessus between patients with cystic fibrosis: a retrospective cohort study. Lancet. 2013;381:1551–60.CrossRefGoogle Scholar
  15. 15.
    Fowler CJ, Olivier KN, Leung JM, et al. Abnormal nasal nitric oxide production, ciliary beat frequency and toll-like receptor response in pulmonary nontuberculous mycobacterial disease epithelium. Am J Respir Crit Care Med. 2013;187:1374–81.CrossRefGoogle Scholar
  16. 16.
    Aksamit TR, O’Donnell AE, Barker A, Olivier KL, et al. Adult patients with bronchiectasis: a first look at the US Bronchiectasis Research Registry. Chest. 2017;151:982–92.CrossRefGoogle Scholar
  17. 17.
    Lin J-L, Xu J-F, Qu J-M. Bronchiectasis in China. Ann Am Thorac Soc. 2016;5:609–16.CrossRefGoogle Scholar
  18. 18.
    Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, et al. An official ATS/ISDA statement: diagnosis, treatment and prevention of Nontuberculous mycobacterial disease. Am J Respir Crit Care Med. 2007;175:367–416.CrossRefGoogle Scholar
  19. 19.
    Kim RD, Greenberg DE, Ehrmantraut ME, et al. Pulmonary nontuberculous mycobacterial disease: prospective study of a distinct pre-existing syndrome. Am J Respir Crit Care Med. 2008;178:1066–74.CrossRefGoogle Scholar
  20. 20.
    Colombo RE, Hill SC, Claypool RJ, Holland SM, Olivier KN. Familial clustering of pulmonary nontuberculous mycobacterial disease. Chest. 2010;137:629–34.CrossRefGoogle Scholar
  21. 21.
    O’Connell ML, Birkenkamp KE, Kleiner DE, et al. Lung manifestations in an autopsy-based series of pulmonary or disseminated nontuberculous mycobacterial disease. Chest. 2012;141:1203–9.CrossRefGoogle Scholar
  22. 22.
    Fujita J, Ohtsuki Y, Shigeto E, et al. Pathologic findings of bronchiectasis caused by mycobacterium avium intracellulare complex. Respir Med. 2003;97:933–8.CrossRefGoogle Scholar
  23. 23.
    Brode SK, Jamieson FB, Ng R, et al. Increased risk of mycobacterial infections associated with anti-rheumatic medications. Thorax. 2015;70:677–82.CrossRefGoogle Scholar
  24. 24.
    Shimon G, Yonit WW, Gabriel I, et al. The “tree in bud” pattern on chest CT: radiologic and microbiologic correlation. Lung. 2015;193:823–9.CrossRefGoogle Scholar
  25. 25.
    Miller WT, Panosian JS. Causes and imaging patterns of tree-in-bud opacities. Chest. 2013;144:1883–92.CrossRefGoogle Scholar
  26. 26.
    DelGuidice G, Bianco A, Cennamo A, et al. Lung and nodal involvement in nontuberculous mycobacterial disease: PET/CT role. Biomed Res Int. 2015;25:8. https://dx.doi.org/10.1155/2105/353202
  27. 27.
    Martinez-Garcia M-A, de la Rosa Carrillo D, Soler-Cataluna J-J, et al. Prognostic value of bronchiectasis in patients with moderate-to severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2013;187:823–31.CrossRefGoogle Scholar
  28. 28.
    Vinnard C, Longworth S, Mezochow A, et al. Deaths related to non-tuberculous mycobacterial infections in the United States, 1999–2014. Ann Am Thorac Soc. 2016;13:1951–55.Google Scholar
  29. 29.
    Qvist T, Taylor-Robinson D, Waldmann E, et al. Comparing harmful effects of non-tuberculous mycobacteria and Gram negative bacteria on lung function in patients with cystic fibrosis. J Cyst Fibros. 2016;15:380–5.CrossRefGoogle Scholar
  30. 30.
    Yamasaki K, Mukae H, Kawanami T, et al. Possible role of anaerobes in the pathogenesis of nontuberculous mycobacterial infection. Respirology. 2015;20:758–65.CrossRefGoogle Scholar
  31. 31.
    Rogers GB, Bruce KD, Martin ML, Burr LD, Serisier DJ. The effect of long-term macrolide treatment on respiratory microbiota composition in non-cystic fibrosis bronchiectasis: an analysis from the randomised, double-blind, placebo-controlled BLESS trial. Lancet Respir Med. 2014;2:988–96.CrossRefGoogle Scholar
  32. 32.
    Dirac MA, Horan KL, Doody DR, Meschke JS, et al. Environment or host? A case-control study of risk factors for mycobacterium avium complex lung disease. Am J Respir Crit Care Med. 2012;186:684–91.CrossRefGoogle Scholar
  33. 33.
    Griffith DE, Brown-Elliott BA, Langsjoen B, Zhang Y, et al. Clinical and molecular analysis of macrolide resistance in mycobacterium avium complex lung infection. Am J Respir Crit Care Med. 2006;174:928–34.CrossRefGoogle Scholar
  34. 34.
    Smith AR, Bell SC, Bojcin S, Bryon M, et al. European cystic fibrosis society standards of care: best practice guidelines. J Cyst Fibros. 2014;13:S23–42.CrossRefGoogle Scholar
  35. 35.
    Pasteur MC, Bilton D, Hill AT, et al. British Thoracic Society guideline for non-CF bronchiectasis. Thorax. 2010;65:i1–58.CrossRefGoogle Scholar
  36. 36.
    Volsko TA. Airway clearance therapy: finding the evidence. Respir Care. 2013;58:1669–78.CrossRefGoogle Scholar
  37. 37.
    Elkins MR, Robinson M, Rose BR, et al. A controlled trial of long term hypertonic saline in patients with cystic fibrosis. N Engl J Med. 2006;354:229–40.CrossRefGoogle Scholar
  38. 38.
    Kellett F, Robert NM. Nebulised 7% saline improves lung function and quality of life in bronchiectasis. Respir Med. 2011;105:1831–5.CrossRefGoogle Scholar
  39. 39.
    Hill AT. Macrolides for clinically significant bronchiectasis in adults: who should receive this treatment? Chest. 2016;150:1187–93.CrossRefGoogle Scholar
  40. 40.
    Binder AM, Adjemian J, Olivier KN, Prevots DR. Epidemiology of nontuberculous mycobacterial infection and associated chronic macrolide use among patients with cystic fibrosis. Am J Respir Crit Care Med. 2013;188:807–12.CrossRefGoogle Scholar
  41. 41.
    Elborn JS, Tunney MM. Macrolides and bronchiectasis. Clinical benefit with a resistance price. JAMA. 2013;309:1295–6.CrossRefGoogle Scholar
  42. 42.
    Martinez-Garcia MA, Soler-Cataluna JJ, Catalan-Serra P, Roman-Sanchez P, Perpina Tordera M. Clinical efficacy and safety of budesonide-formoterol in non-cystic fibrosis bronchiectasis. Chest. 2012;141:461–8.CrossRefGoogle Scholar
  43. 43.
    Mohanka M, Khemasuwan D, Stoller JK. A review of augmentation therapy for alpha-1 antitrypsin deficiency. Expert Opin Biol Ther. 2012;12:685–700.CrossRefGoogle Scholar
  44. 44.
    Quinti I, Soresina A, Geurra A, Rondelli R, et al. Effectiveness of immunoglobulin replacement therapy on clinical outcomes in patients with primary antibody deficiencies: results from a multicenter prospective cohort study. J Clin Immunol. 2011;31:315–22.CrossRefGoogle Scholar
  45. 45.
    Koh WJ, Lee JH, Kwon YS, Lee KS, et al. Prevalence of gastroesophageal reflux disease in patients with nontuberculous mycobacterial lung disease. Chest. 2007;131:1825–30.CrossRefGoogle Scholar
  46. 46.
    Henkle E, Aksamit T, Barker A, Daley CL, et al. Patient-centered research priorities for pulmonary nontuberculous mycobacterial (NTM) infection. An NTM research consortium workshop report. Ann Am Thorac Soc. 2016;13:S379–84.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Division of Pulmonary, Critical Care and Sleep MedicineGeorgetown University Medical CenterWashington, DCUSA

Personalised recommendations